SK Life Science, Inc.
42
1
3
33
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.1%
3 terminated/withdrawn out of 42 trials
91.7%
+5.2% vs industry average
36%
15 trials in Phase 3/4
12%
4 of 33 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
Role: lead
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Role: lead
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Role: lead
Cenobamate Open-Label Extension Study for YKP3089C025
Role: lead
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Role: lead
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Role: lead
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Role: lead
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Role: lead
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
Role: lead
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
Role: lead
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
Role: lead
Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
Role: lead
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Role: lead
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Role: lead
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
Role: lead
Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
Role: lead
Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS
Role: lead
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Role: lead
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Role: lead
Cenobamate Expanded Access Program (EAP)
Role: lead